Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
Public ClinicalTrials.gov record NCT04305054. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Substudy 02B is part of a larger research study where researchers are looking for new ways to treat advanced melanoma that has not been treated before. The larger study is the umbrella study. Researchers want to know if adding other treatments to pembrolizumab can treat advanced melanoma. The goals of this study are to learn: * About the safety and how well people tolerate pembrolizumab given with other treatments * How many people have melanoma that responds (gets smaller or goes away) to treatment
Study identification
- NCT ID
- NCT04305054
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 335 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Biological
- Vibostolimab Biological
- Pembrolizumab/Quavonlimab Biological
- Lenvatinib Drug
- Favezelimab/Pembrolizumab Biological
- ATRA Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2020
- Primary completion
- May 17, 2026
- Completion
- May 17, 2026
- Last update posted
- May 27, 2026
2020 – 2026
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Angeles Clinic and Research Institute ( Site 2009) | Los Angeles | California | 90025 | — |
| UCLA Hematology & Oncology ( Site 2004) | Los Angeles | California | 90095 | — |
| Providence Saint John's Health Center ( Site 2010) | Santa Monica | California | 90404 | — |
| University of Colorado, Anschutz Cancer Pavilion ( Site 2012) | Aurora | Colorado | 80045 | — |
| University of Florida College of Medicine-UF Health Cancer Center/Clinical Trials Office ( Site 2026) | Gainesville | Florida | 32608 | — |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 2022) | Baltimore | Maryland | 21287 | — |
| R.J. Zuckerberg Cancer Center ( Site 2032) | Lake Success | New York | 11042 | — |
| NYU Clinical Cancer Center ( Site 2002) | New York | New York | 10016 | — |
| Duke Cancer Institute ( Site 2005) | Durham | North Carolina | 27710 | — |
| Martha Morehouse Tower ( Site 2020) | Columbus | Ohio | 43221 | — |
| Oregon Health & Science University ( Site 2013) | Portland | Oregon | 97239 | — |
| University of Pennsylvania Abramson Cancer Center ( Site 2008) | Philadelphia | Pennsylvania | 19104 | — |
| West Cancer Center - East Campus ( Site 2014) | Germantown | Tennessee | 38138 | — |
| Mays Cancer Center ( Site 2025) | San Antonio | Texas | 78229 | — |
| Inova Schar Cancer Institute ( Site 2011) | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04305054, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 27, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04305054 live on ClinicalTrials.gov.